Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers.

Journal of clinical psychopharmacology - 1 Apr 2006

Güzey Cüneyt, Spigset Olav

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Genotype
Share to Paroxetine
Share to Polymorphism, Genetic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 16633156
DOI: 10.1097/01.jcp.0000203225.79364.85

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers.PMID 16633156Read ↗

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.Semantic proximity Read ↗

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.Semantic proximity Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.Semantic proximity Read ↗

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.Semantic proximity Read ↗

Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.Semantic proximity Read ↗

Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient.Semantic proximity Read ↗

Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.Semantic proximity Read ↗

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.Semantic proximity Read ↗

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.Semantic proximity Read ↗

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.Semantic proximity Read ↗

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.